Contrast enhancement and metabolic changes detected with functional MR imaging can help interventional radiologists anticipate the effects of transarterial chemoembolization on primary and metastatic tumors of the liver.
Contrast enhancement and metabolic changes detected with functional MR imaging can help interventional radiologists anticipate the effects of transarterial chemoembolization on primary and metastatic tumors of the liver.
Clinical trials from Johns Hopkins University and Northwestern University come on the heels of a third study showing that contrast-enhanced and diffusion-weighted MRI can confirm the effects of transarterial chemoembolization (TACE) on liver metastases from neuroendocrine tumors. Results were presented March 17 at the 2008 Society of Interventional Radiology meeting.
Northwestern medical student Neel K. Naik and colleagues enrolled 21 patients with hepatocellular carcinoma who underwent TACE and pre- and postprocedural 1.5T gadolinium-enhanced T1-weighted MR and DWI with follow-up at one and three months. They found DWI changes a few weeks after treatment began that were useful for predicting TACE effects two months before they actually took place and became evident with anatomic MRI and other types of imaging.
Previous research has shown that functional MRI can characterize liver lesions, but no study to date had looked at the possibility of predicting response to TACE, Naik said.
In another study, interventional radiology fellow Dr. Josephina A. Vossen and colleagues at Johns Hopkins evaluated 19 patients with unresectable primary or metastatic liver tumors treated with TACE. Patients underwent unenhanced/contrast-enhanced MRI and MR spectroscopy before and after a single treatment. Two radiologists interpreted results by consensus.
They found 11 patients with successful tumor embolization showed loss of choline peak on MR spectroscopy, significant increase in apparent diffusion coefficient values (22%, p = 0.004), and significant decrease in tumor arterial and venous enhancement (43%, p = 0.005 and 40%, p = 0.002, respectively). Patients with no evidence of tumor response had a stable choline concentration, tumor enhancement, and ADC.
"These functional findings preceded tumor regression in size and may be utilized to detect early therapeutic response," Vossen said.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.